Poynard T. et al; A prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C; Cinchem 2004
“Only a minor proportion of patients with chronic hepatitis C have an adequate sized biopsy. Most of the discordant results were attributable to biopsy failures.”

Poynard T. et al; Meta-analysis of FibroTest in the diagnosis of fibrosis in the 4 most common liver diseases; BMC Gastroenterology 2007
"FibroTest is an alternative to liver biopsy for the diagnosis of fibrosis in patients with chronic hepatitis C as well as B, alcoholic liver diseases and non alcoholic steatosis. FibroTest’s diagnostic value is similar for intermediary or extreme stages diagnosis and for diagnosis of patient presenting with normal ALT."

Robert P. Myers et al; Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B; Journal of hepatology 2003
“The aminotransferases and an index including five biochemical markers are accurate noninvasive markers of HBV-related activity and fibrosis, respectively.”

NGO Y. ET AL; AN ACCURATE DEFINITION OF THE STATUS OF INACTIVE HEPATITIS B VIRUS CARRIER BY A COMBINATION OF BIOMARKERS (FIBROTEST-ACTITEST) AND VIRAL LOAD; PLOSONE 2008
“In patients with chronic hepatitis B, a combination of FibroTest-ActiTest and viral load testing accurately defined the prognosis and the inactive carrier status.”

Myers R. et al; Biochemical Markers of Liver Fibrosis: A Comparison With Historical Features in Patients With Chronic Hepatitis C; The American Journal of Gastroenterology 2002
“(…) is more accurate than an index of historical features, the addition of which to the existing index was not helpful. The markers (…) are widely available, and this validated instrument represents the most discriminative tool available for the noninvasive prediction of HCV-related fibrosis”

Sebastiani G. et al; Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C; Journal of hepatology 2006
“Stepwise combination of non-invasive markers of liver fibrosis improves the diagnostic performance in chronic hepatitis C. Need for liver biopsy is reduced by 50–70% but cannot be completely avoided.”

Poynard T. et al; Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV Fibrosure) and necrosis (ActiTest) in patients with chronic hepatitis C; Comparative Hepatology 2004
“Based on these results, the use of the biochemical markers of liver fibrosis (FibroTest) and necrosis (ActiTest) can be recommended as an alternative to liver biopsy for the assessment of liver injury in patients with chronic hepatitis C. In clinical practice, liver biopsy should be recommended only as a second line test, i.e., in case of high risk of error of biochemical tests.”

Poynard T. et al; Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon Alfa-2b and Ribavirin; Hepatology 2003
“In conclusion, these biochemical markers of fibrosis and activity could be used as surrogate markers for liver biopsy in patients with chronic hepatitis C, both for the initial evaluation and for follow-up.”

Poynard T. et al; Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial; Journal of viral Hepatitis 2002
“This (FibroTest) fibrosis index could be used as a surrogate marker of the antifibrotic effect of treatments in patients with chronic hepatitis C.”

Myers R. et al; Biochemical markers of liver fibrosis: A comparison with historical features in patients with chronic Hepatitis C; Journal of Gastroenterology 2002
“A simple index including age, sex, and five biochemical markers accurately predicts significant hepatitis C-related fibrosis. This index is more accurate than an index of historical features, the addition of which to the existing index was not helpful.”

Imbert-Bismut F. et al; Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, The Lancet 2001
“A combination of basic serum markers could be used to substantially reduce the number of liver biopsies done in patients with chronic HCV infection.”

Ngo Y. et al; A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic Hepatitis C; Clinical Chemistry 2006
“The FibroTest measurement of HCV biomarkers has a 5-year prognostic value similar to that of liver biopsy.”

Thabut D. et al; Non-invasive prediction of fibrosis in patients with chronic hepatitis C; Hepatology 2003
“this retrospective comparison suggests that the Fibrotest provides a more accurate estimate of HCV-related fibrosis than the index of Forns et al.1 Prospective comparisons in additional centers are warranted to confirm this finding.”

Poynard T. et al; FibroTest-FibroSure: towards a universal Biomarker of liver fibrosis; Future drugs 2005
“(…) due to the limitations and risks of biopspy (…), liver biopsy should no longer be considered mandatory”

Poynard T. et al; Serum markers of liver fibrosis, Hepatology 2003
“Non-invasive biochemical markers could be used as an alternative to liver biopsy at least in chronic hepatitis C and B.”

Thabut D. et al; Diagnostic value of fibrosis biochemical markers (FibroTest) for the screening of oesophagal varices in patients with chronic liver diseases; LiverInt 2006
“(…) could help clinicians predict endoscopic portal hypertension, thereby reducing the indication for endoscopic varices screening and simplifying medical management”

Thabut D. et al; Non-invasive diagnosis of large scale oesophagal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study, Liver international 2006
“FibroTest could aid in the diagnosis of LOV and may therefore reduce the indication of endoscopic screening in cirrhotic patients.”

Thabut D. et al; Relationship between the Fibrotest and portal hypertension in patients with liver disease; Aliment Pharmacol Ther. 2007
“(…) could help clinicians predict portal hypertension, thereby reducing the indication of endoscopic screening for varices and simplifying medical management”

Jacqueminet S. et al; Screening of advanced fibrosis with FibroTest in diabetic patients with hepatitis; Comparative Hapatology 2004
“(…) This study shows that biochemical markers can be very useful to screen advanced fibrosis in diabetic patients with hepatitis C in order to reduce mortality."

Ratziu V. et al; Diagnostic value of biochemical markers (FibroTest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterology 2006
“In patients with NAFLD, Fibrotest, a simple and non-invasive quantitative estimate of liver fibrosis, reliably predicts extensive fibrosis and cirrhosis. This should improve the identification of the population at risk of significant liver injury and reduce the number of unnecessary liver biopsies.”

Naveau S. et al; Diagnostic value of biochemical markers (FibroTest) for the prediction of liver fibrosis in patients with chronic alcoholic liver disease, Gastroenterol hepatol 2005.
“ In heavy drinkers, Fibrotest is a simple and non-invasive quantitative estimate of liver fibrosis with a better sensitivity than hyaluronic acid. Fibrotest may reduce the need for liver biopsy”

Lamireau T et al; Non-invasive diagnosis of liver fibrosis: FibroTest’s validation in children; Hepatology 2005 – Abstract
� FibroTest shown a similar diagnostic value in childern as in adults �

Thabut D et al; Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?; Journal of Gastroenterology 2006
“In patients ≥65 yr, (…) biochemical markers seem particularly useful as a noninvasive alternative to liver biopsy in this population.”

Myers R. et al ; Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients, AID 2003
“(…) accurately predicts significant fibrosis in patients with HIV/HCV co-infection, and may substantially reduce the necessity for liver biopsy.”

Varaut A. et al; Diagnostic accuracy of the FibroTest in hemodialysis and renal transplant patients with chronic hepatitis C; Transplantation 2005
“(…)has a diagnostic value in haemodialysis and renal transplant patients which is similar to that reported in the general population (75%) and its use could avoid 32% of liver biopsies if it were interpreted in detail in nephrology patients.”

FRIEDRICH-RUST ET AL, NONINVASIVE ASSESSMENT OF LIVER FIBROSIS IN PATIENTS WITH FONTAN CIRCULATION USING TRANSIENT ÉLASTOGRAPHIE AND BIOCHEMICAL FIBROSIS MARKERS, J THORAC CARDIOVASC SURG 2008
“The present study shows that patients who undergo the Fontan procedure are at increased risk of developing liver fibrosis and liver cirrhosis. The risk increases with the age of the patient and the time interval since the Fontan procedure. The noninvasive measurement of liver fibrosis using transient elastography and fibrosis marker scores can be a useful tool to identify patients at risk and for noninvasive surveillance”

Halfon P. et al; A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease; Comparative Hepatology 2002
“The variability of FibroTest and ActiTest was acceptable without clinical consequences for the prediction of the stage of liver fibrosis and grade of activity. Standardized methods and assay calibration should be used and expression of alanine aminotransferase and γ-glutamyl transpeptidase in multiples of the upper limit of reference values should not be employed.”

Munteanu M. et al; Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest); Comparative Hepatology 2004
“ The intra-individual variation of biochemical markers was low, and it was shown that measurements of FibroTest, ActiTest and their components are not significantly modified by meal intake. This fact makes the screening of patients at risk of chronic liver diseases more convenient.”

Imbert-Bismut F. et al; Intra-laboratory analytical variability of biochemical markers of fibrosis FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors; Clinical chemistry 2004
“ In conclusion, Fibrotest and Actitest are easily available biological markers for fibrosis and activity lesions that can be used as alternatives, or in addition, to liver biopsy for the follow-up of patients with hepatitis C. Their intra-laboratory analytical variability is low and the worldwide improvement in transferability of biochemical parameter results will enhance Fibrotest and Actitest reliability in the immediate future.”

Le Calvez S. et al; The predictive values of FibroTest vs. APRI for fibrosis diagnosis in patients with chronic hepatitis C; Hepatology 2004
“(…) In conclusion, these comparisons suggest that FibroTest provides a more accurate estimate of HCV-related fibrosis than the Wai indexes”

Poynard T. et al; Biomarkers of liver fibrosis; in Press
“Practices are evolving rapidly and in France a nationwide survey recently found that among 546 hepatologists, 81% used non-invasive biomarker (FibroTest™-ActiTest™) (FT-AT) and 32% used elastography (Fibroscan™) (FS), with a dramatic decrease in the use of liver biopsy for more than 50% of patients with chronic hepatitis C, and with a subsequent increase in the number of patients treated ”

Thabut D. et al; Non-invasive prediction of fibrosis in patients with chronic hepatitis C; Hepatology 2003
“ In conclusion, this retrospective comparison suggests that the Fibrotest provides a more accurate estimate of HCV-related fibrosis than the index of Forns et al.1 Prospective comparisons in additional centers are warranted to confirm this finding.”

Hilleret M.N. et al; Diagnostic accuracy of MP3 score compared to hyaluronate and FibroTest for evaluating liver fibrosis in chronic hepatitis B
“ Our results confirm that MP3, HA and FT have a good accuracy in HBV infection in predicting extensive fibrosis, especially when used in combination. They could be especially usefull in management of inactive carriers who might have cirrhosis. Diagnostic performance seems to be lower in discriminating mild vs moderate fibrosis than that observed in HCV infection.”

Myers R. et al; Biochemical markers of fibrosis in patients with chronic hepatitis C; Digestive Diseases ans Sciences 2003
“ In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers.”

Callewaert N. et al; Non-invasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics; Nature medicine 2004
“Additional Serum markers with high sensivity are therefore required. In this study we used FibroTest to complement our new GlycoCirrhoTest, and show that the combination of both biomarkers can achieve the desired >95% specificity with high sensivity”

Castera L. et al; Prospective comparison of transient Elastography, FibroTest, Apri and liver biopsy for the assessment of fibrosis in chronic hepatitis C; Gastroenterology 2005
“ FibroScan� is a simple and effective method for assessing liver fibrosis, with similar performance to FibroTest� and APRI. Combined use of FibroScan� and FibroTest� to evaluate liver fibrosis could avoid biopsy in most patients with chronic hepatitis C.”

Adams A. et al; Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection; Clinical chemistry 2005
“ A model of 4 serum markers plus age and sex provides clinically useful information regarding different fibrosis stages among hepatitis C patients.”

F�rard G. et al; Inter-method calibration of alanine aminotransferase (ALT) and gama glutamyltransferase (GGT) results: application to FibroTest and ActiTest scores; Clinical chemistry 2006
“ For each enzyme, it also permitted the retention of a common reference interval for a set of calibrated methods and the improvement of inter-laboratory coherency of Fibrotest and Actitest scores.”

Morra R et al; FibroMax: towards a new universal biomarker of liver disease?, Future drugs 2007
“They allow a quantitative assessment of both fibrosis and steatosis and, according to the cause of liver disease, an assessment of the necroinflammatory histological activity. (…) These tests, which are now available worldwide, can facilitate the screening and management of fibrotic liver diseases including Hepatitis B, hepatitis C, AFLD and NAFLD”

Poynard T. et al; The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.; CompHepatol 2005
“ SteatoTest is a simple and non-invasive quantitative estimate of liver steatosis and may reduce the need for liver biopsy, particularly in patients with metabolic risk factor.”

Poynard T. et al; Diagnostic value of biochemical markers (NashTest) for the prediction of NASH in patients with non-alcoholic fatty liver disease, BMC Gastroenterology 2006
“In patients with non-alcoholic fatty liver disease, NashTest, a simple and non-invasive biomarker reliably predicts the presence or absence of NASH.”

Thabut D. et al; The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease, Journal of hepatology 2006
“In heavy drinkers, AshTest is a simple and non-invasive quantitative estimate of alcoholic hepatitis. The use of AshTest may reduce the need for liver biopsy, and therefore allow an earlier treatment of alcoholic hepatitis.”